ASCO 2024

Immunotherapy makes a difference in survival in eTNBC

Prognostic value of ctDNA in therapeutic strategies;…

Adjuvant endocrine therapy for ER-low EBC

Personalized neoadjuvant therapy for high-risk breast…

AI for the prediction of disease progression

Ribociclib is also effective in N0 HR+/HER2− EBC

Advantage for node-negative patients

ctDNA analysis in monarchE

One step closer to chemo-free therapy for HR+/HER2+…

Expanding T-DxD use to HER2 ultra-low - the success…

Reassuring and clarifying new data for CDK4/6…

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Responder premenopausal

Is there still a place for endocrine therapy in HER2+…

Heterogenity of ER+ disease

New data on the omission of chemotherapy in young…

Triple positive mBC - chemotherapy unnecessary?

Leptomeningeal metastases in HER2+ mBC

Systemic therapy of HER2+ patients with brain…

HER2+ mBC 1stL T-Dxd

T-DXD continues its impressive track record for MBC…

The ADC revolution continues - ctDNA takes the next…

Broaden T-DXD as therapy standard for HER2low and…

Decreasing SG related toxicity with profilatic G-CFS

Ultra low - ultra good?

Important OS benefit with T-Dxd in HER2+ mBC

Novel ADC-ICI combination therapy

Sacituzumab tirumotecan - a new powerful ADC for…

Already more in the 1stL?

INAVO120 - updated results

First-line inavolisib/placebo + palbociclib +…

Chemo-free, CDK4/6 inhibitor-based combination active…

CDK4/6 rechallenge

Chemo-free regimen in HER2+ luminal breast cancer

CDK4/6i effective in premenopausal patients as well

Endocrine therapy with Palbociclib + Trastuzumab

Regime senza chemioterapia nel carcinoma mammario…

Sacituzumab tirumotecan – nowy aktywny koniugat w…

Le traitement endocrinien a-t-il encore sa place dans…

Importante beneficio en la supervivencia global con…

La révolution de l'ADC se poursuit / ctDNA franchit une…

Leczenie bez chemioterapii, oparte na inhibitorze…

INAVO120: risultati aggiornati

C'è ancora posto per la terapia endocrina nel BC HER2+?

CDK4/6 rechallenge

Espansione dell'uso di T-DxD nelle pazienti con…

PSMA-PET CT: Ready for clinical practice or a PROMISE…

Focus on Quality of Life

Interesting data - but not practice changing

ARASENS Post hoc analysis: Therapy after progression

mCRPC: Who benefits from which measures?

Unlocking Insights: The ALLIANCE Trial redefining…

EMBARK: Quality of Life

Important QoL data

The evolving role of PSMA-PET with new agents

RCT in mCRPC

Unveiling the Potential: PSMA-PET in Prostate Cancer…

Deciphering EMBARK: Exploring Enzalutamide's Impact on…

mCRCP CYCLONE 2 study

Exploring the CHAARTED TRIAL: Optimizing Treatment…

Radionukleotides - the next step forward

Perioperative treamtent in MIBC - new data for the use…

Effect of an immune diet on the outcome after radical…

Preoperative use of sacituzumab govitecan

ASCO 2024: Time for the rare GU tumors?

Treatment of urachal carcinoma

Biomarkers and long-term outcomes in pts with low tumor…

What to do with Cis Gem Nivo?

Quality of life not affected by i. v. Pembro

MI-UC - News from EVP standard

Modified FOLFIRINOX therapy as a good option for…

The Role of Topoisomerase Inhibitors in the…

The future of sacituzumab govitecan

Interim analysis of the SURE-01/02 study

El futuro de sacituzumab govitecan

Biomarcadores y resultados a largo plazo en pacientes…

ASCO24: Bladder cancer highlights

El papel de los inhibidores de topoisomerasa en el…

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms…

Advancing Our Understanding of Biological Mechanisms…

Combination is superior to monotherapy - how do we…

Adjuvant KIM-1 as prognostic & predictive biomarker

New IMDC risk group - very favorable

Biomarker analysis of KN426 & CLEAR

nccRCC

The never ending saga of biomarkers

KIM-1: Will have a major impact

KIM-1 - old wine in new bottles

Treatment of favorable prognosis mRCC patients:…

NIVO+CABO: significantly longer therapy-free time

The search of the ideal biomarker in advanced renal…

DFF332 a novel HIF inhibitor

Metastasized chromophobe RCC

Combination therapies for chromophobe renal cell…

Belzutifan in earlier lines in advanced ccRCC

New HIF inhibitor in clear cell RCC

Tratamiento del cancer renal avanzado de pronostico…

End of the story in EGFRm disease?

CheckMate 816: 4-year update

Gamechanger in EGFR-mutated NSCLC

Liquid biopsy in curative situation

4y follow-up of CheckMate 816

ctDNA predicts outcome in patients treated with…

Perioperative chemotherapy and N2 status

Osimertinib improves PFS in stage III

Confirmed efficacy of periop IO in N2 R-NSCLC

Stadium III EGFR+: now permanently Osimertinib?!

4-year efficacy of Keynote-799 and ctDNA

Cambio temprano en el tratamiento estándar del EGFR+…

Le traitement adjuvant par osimertinib apres CTRT : …

KRAS in NSCLC - a lot to come

Update for EGFR-positive NSCLC

TROP2-targeting ADCs: where a we heading?

Adagrasib for KRASG12C mutation 2nd line

KRASG12C - the story continues

EGFR+ NSCLC - amivantamab-based combination therapy

KRAS building on single agent therapy

Confirmed efficacy of adagrasib in KRASG12C

The end for local therapy for oligometastatic disease

ASCO 2024 highlights

ADCs - moving landscapes. Subgroups remain to be…

Subcut amivantamab - the future

Telehealth is just as effective as a face-to-face visit…

BAY2927088 - Promising Her2-Inhibitor in NSCLC

ALK+ NSCLC - CROWN revisited

Lorlatinib convincing in ALK mutation 1st line

Het einde van lokale therapie voor oligometastatische…

La télésanté est aussi efficace qu'une consultation…

ASCO 2024 highlights

ASCO 2024 highlights

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

New SoC for LD-SCLC

Tarlatamab shows activity in patients with brain…

LD-SCLC: What´s about PCI?

Finally, change for LS-SCLC

Le traitement d'entretien avec le durvalumab est le…

Chemo-immuno in mesothelioma - update

Is adjuvant treatment still standard in macroscopic,…

Is the triplet ready for phase 3?

Is the induction treatment the new strategy for…

10 years follow up - immunotherapy for BRAF-mutated…

Personalized mRNA-vaccination: Practice changer of the…

A new therapy benchmark for brain-met melanoma patients

Adjuvant therapy with dabrafenib and trametinib - final…

Identifying patients with longterm benefits during…

Consolidation of the use of IO in clinically detectable…

Impactful studies from ASCO 24 II: Combi-AD

Impactful studies from ASCO 24 I: NADINA

Intralesional therapy with Daromun

Emerging rescue therapies for PD1 refractory melanoma

A new triplet for metastatic melanoma

Vaccine in combination with nivolumab for PDL1…

Neoadjuvant intratumoral therapy with Daromun in…

3-year update on mRNA vaccines in melanoma

Longterm survival after adjuvant targeted therapy

Promising Results: Triple combination therapy in…

Triple checkpoint blockade - a new approach?

Survival data for TT with dabrafenib and trametinib

Impactful studies from ASCO 24 III: Cell-therapy

mRNA vaccine plus pembrolizumab in adjuvant therapy

No differences in PFS between the two study arms

New oncolytic immunotherapy (RP1) after PD-1 failure

TIL therapy for metastatic melanoma

Progress in neoadjuvant therapy with IO

Neoadjuvant immunotherapy treatment for melanoma

Lentigo maligna therapy

Consolidación del uso de IO en melanoma en estadio III…

No hubo diferencias en la PFS entre los dos brazos del…

Risultati promettenti: Tripla terapia di combinazione…

New therapeutic approaches: Get over PD1 resistances?

New perspectives in HPV+ r/m HNSCC

New insights in localized HNSCC

Clear cell carcinomas benefit from IO therapy

New idea: anti-digest for EC?